Document is current
Any future updates will be listed below
-
Authors
Banerjee, Jineta
Lyu, Yang
Makri, Stavriani C. https://orcid.org/0009-0008-6940-9468
Scott, Alexandra J.
Zhang, Lindy
Calizo, Ana
Pollard, Kai
Yang, Kuangying https://orcid.org/0000-0002-6992-9585
Gross, John M.
Lucas, Calixto-Hope G. https://orcid.org/0000-0002-8347-9592
Wang, Jiawan https://orcid.org/0000-0002-2137-1826
Levin, Adam S.
Belzberg, Allan J.
Romo, Carlos G.
Allaway, Robert J. https://orcid.org/0000-0003-3573-3565
Blakeley, Jaishri O.
Hirbe, Angela C.
Pratilas, Christine A. https://orcid.org/0000-0002-7116-0605
-
Funding
Funding for this research was provided by:
Neurofibromatosis Therapeutic Acceleration Program
- License Information
-
More Information
Article History
Received: 30 July 2024
Accepted: 20 June 2025
First Online: 15 July 2025
Competing interests
: C.A.P. has received research grants from Kura Oncology and Novartis Institutes for Biomedical Research (unrelated to this manuscript); and consulting fees from Day One Therapeutics (unrelated). J.W. and C.A.P. are inventors on a patent application (WO2022234409A1) held/submitted by the Johns Hopkins University and Novartis that covers compounds and compositions for the treatment of MPNST. A.J.B. has received consulting fees from AstraZeneca (unrelated to this manuscript). J.O.B. participates in advisory boards for SpringWorks Therapeutics and Alexion (unrelated to this manuscript). A.C.H. has served on advisory boards for AstraZeneca/Alexion, SpringWorks Therapeutics, and Aadi Subsidiary, Inc, has had grant funding from Tango therapeutics, and has licensing agreement with Boehringer Ingelheim GmbH (unrelated to this manuscript). The other co-authors declare that they have no competing interests.
